Innovations in Cardiovascular Disease Management: Latest surgical procedures, drugs and medical devices

Table of Contents

• The Management of Cardiovascular Disease
• Cardiovascular and Interventional Procedures
• Emerging Coronary Stents and Stent Systems
• Innovations in Minimally Invasive Cardiac Surgery
• Cardiovascular Drugs in Early Stage Development
• New and Emerging Cardiovascular Drugs

• Summary
• Introduction
• The Global Burden of Cardiovascular Disease
• CVD remains the leading cause of death in the United States
• CVD Rates in Central and Eastern Europe
• Noncommunicable Diseases in the Developing World
• Background to the Major Cardiovascular Conditions
• Coronary Artery Disease (CAD)
• Atherosclerosis
• Angina Pectoris
• Acute Myocardial Infarction (MI)
• Heart Valve Disorders
• Aortic heart valve
• Mitral Valve Disease
• Pulmonary Valve Disease
• Tricuspid Valve Disease
• High Blood Pressure: Hypertension
• Heart Rhythm Disorders (Heart Arrhythmia)
  • Peripheral Vascular Disease
  • Peripheral Artery Disease (PAD)
  • Peripheral Venous Disorders (PVD)
  • Stroke or Cerebrovascular Accidents (CVA)
  • Ischaemic Stroke
  • Haemorrhagic stroke

• Summary
• Introduction to Percutaneous Coronary Interventions
• Indications for PCI
• PCI Procedural Volumes
• PCI Used Primarily to Treat Unstable Angina and acute ST-elevation MI
• Inter-country Variance in PCI Procedural Rates
• China and India: Huge growth potential and market development
• Latest Developments in PCI Procedures
• Embolic Protection Devices
• Current Products
• Development Stage Products and Current Status
• Future Technologies and Trends
• Coronary Atherectomy
• Rotational Coronary Atherectomy (Rotoblation)
• Directional Coronary Atherectomy (DCA)
• Orbital Atherectomy
• Ablative laser-assisted angioplasty

• Summary
• Emerging Coronary Stents and Stent Systems
• Key Events
• Introduction of Drug-Eluting Stents (DES)
• Development of Drug-Eluting Stents
• Sirolimus (Rapamycin)
• Paclitaxel
• Tacrolimus
• Everolimus (RAD-001)
• Zotarolimus (also called ABT-578)
• DES - Recent News, Product Developments and Clinical Trial Updates
• Market Developments and Forecasts for Drug-Eluting Stents
• Emergence of Bioabsorbable Stents
• Biomaterials and Bioabsorbable Polymers
• Further Coronary Stent Developments and Technological Trends
• Novel Coating Technologies
• Gene Therapy technologies and its Potential Use to Prevent Restenosis
• Coronary Stents and Endothelial Progenitor Cells (EPCs)
• Nanotechnologies and Drug-Eluting Coronary Stents
• Development of Novel Estradiol Containing Drug-Eluting Stents
• Stem-Cell Derived Endovascular Cells

• Summary
• Introduction
• Minimally Invasive Direct Coronary Artery Bypass (MID-CAB)
• Indications for MIDCAB
• Off-Pump Coronary Artery Bypass (OP-CAB)
• Indications for OP-CAB
• Minimally Invasive Port Access
• Indications for Minimally Invasive Port Access
• Robotic Assisted Coronary Artery Bypass (RA-CAB)
• Current and Emerging Technologies
• Robotics in Minimally Invasive Cardiac Surgery
• Robotic Systems
• Computer Aided Cardiac Surgery
• Virtual Reality in Cardiac Surgery
• Laser Heart Surgery or transmyocardial Laser revascularization (TMLR)
• The CO2 Heart Laser System
• The holmium:YAG (yttrium aluminium garnet) laser
• The excimer laser

• Summary
• Introduction
• Early Developments in Key Cardiovascular Disease Classes
• Angina
• Arrhythmiasis
• Atherosclerosis
• Atrial Fibrillation
• Congestive Heart Failure
• Hypercholesterolemia
• Hypertension
• Myocardial Infarction
• Thrombosis

• Summary
• Introduction
• Anti-Hypertensives
• Tekturna (Aliskiren)
• Development of a New Class of Renin Inhibitors
• Exforge (valsartan plus amlodipine)
• CHF-1521
• Cleviprex(TM) (Clevidipine)
• Antihypertensives: Current Pipeline and Late Stage Development
• Cardoxal (MC-4232) (MC-1 cardioprotectant plus lisinopril)
• Darusentan
• Ambrisentan
• Nebivolol
• Zanipress® / Zanitek®
• Thelin™ (Sitaxsentan)
• TBC3711
• Anti-Dyslipidemics
• Pfizer discontinues torcetrapib development
• R1658
• Simcor (Niaspan® (extended-release niacin) and simvastatin (generic Zocor®))
• CRESTOR® (rosuvastatin) and CRESTOR/ABT-335 combination
• Synordia
• Lapaquistat (TAK-475)
• SLx-4090
• AEGR-733
• Compound Number 256073 and 501516
• LBM642
• Dyslipidaemia: Current Pipeline and Late Stage Development
• Anti-Thrombotics
• Rivaroxaban (BAY59-7939)
• Rendix (dabigatran etexilate, BIBR-1048)
• Idraparinux
• Apixaban
• SSR-126517
• Exanta/ximelagatran
• Anti-Thrombotics: Current Pipeline and Late Stage Development
• Anti-Arrhythmics
• Stedicor (Azimilide)
• Multaq (Dronedarone)
• Vernakalalant (RSD 1235)
• Tecadenoson CVT510
• Pulzium IV (Tedisamil)
• Anti-Arrhythmics: Current Pipeline and Late Stage Development

• Methodology Statement
• Primary Data and Information Gathering
• Secondary Data and Information Gathering
• Market Share Analysis and Market Forecast Predictions
• Glossary
• Index

• Figure 1.1: Breakdown of Deaths from Cardiovascular Diseases, USA 2002
• Figure 1.2: Leading causes of death in developing countries, 2002
• Figure 2.3: Use of Percutaneous Coronary Intervention in Europe, 2005
• Figure 3.4: Estimated number of Stent Procedures (BMS & DES) % Total Number of PTCA Procedures
• Figure 3.5: Actual and projected revenues from Coronary Stents, Worldwide sales- 2006
• Figure 3.6: Market Share Analysis, DES v BMS World, 2006

• Table 1.1: Age- and gender-specific incidence of recognised MI
• Table 1.2: Age- and gender-specific incidence of unrecognised MI
• Table 2.3: Estimated volume of cardiovascular procedures by region (US 2002)
• Table 2.4: PCI procedure rates in Selected Countries, 2005
• Table 5.5: Selected Early Stage Anti Anginal Drug Developments
• Table 5.6: Selected Early Stage Anti Arrhythmiasis Drug Developments
• Table 5.7: Selected Early Stage Atherosclerosis Drug Developments
• Table 5.8: Selected Early Stage Atrial Fibrillation Drug Developments
• Table 5.9: Selected Early Stage Congestive Heart Failure Drug Developments
• Table 5.10: Selected Early Stage Hypercholesterolemia Drug Developments
• Table 5.11: Selected Early Stage Hypertension Drug Developments
• Table 5.12: Selected Early Stage Myocardial Infarction Drug Developments
• Table 5.13: Selected Early Stage Thrombosis Drug Developments
• Table 6.14: Characteristics of Major Classes of Lipoproteins
• Table 6.15: AstraZeneca' s Current Anti-Dyslipidaemia Pipeline
• Table 6.16: Classification of Anti-Arrhythmics